⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 1, 2026Open Access

Ivonescimab combined with gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the effectiveness of ivonescimab combined with gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer.
Phase II trial design
Evaluation of treatment efficacy in patients with advanced biliary tract cancer
Combination therapy of ivonescimab, gemcitabine, and cisplatin
Significant improvement in response rates compared to historical controls
Reduction in disease progression observed
Enhanced overall survival noted in the treatment group

Implication

Phase II trial shows efficacy of ivonescimab with chemotherapy in advanced biliary tract cancer, suggesting improved outcomes.

Abstract

Ivonescimab combined with gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: phase II trial results

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

吴逵(Kui Wu) (2026) studied this question.

synapsesocial.com/papers/69fd7e23bfa21ec5bbf06529 https://doi.org/10.26036/cnp0009435

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Ivonescimab plus gemcitabine/cisplatin and stereotactic body radiotherapy as first-line treatment for advanced biliary tract cancer: A single-arm, open-label, phase II exploratory study.Early-Phase Clinical Trial · 2026
2The safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer.2024 · 5 citations
3Dual-Targeted Agent Improves Advanced BTC SurvivalLate-Phase Clinical Trial · 2026
4Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial2025 · 1 citations
5Real-world outcomes of chemoimmunotherapy in advanced biliary tract cancer: a multicenter study with a propensity-matched historical cohortCohort Study · 2026

A phase II trial evaluating liposomal irinotecan combined with capecitabine as second-line therapy for biliary tract cancer.2026
A randomized phase III study of gemcitabine plus cisplatin with S-1 versus gemcitabine plus cisplatin with immune checkpoint inhibitor in unresectable biliary tract cancer.2026
EORTC-1607-GITCG/ABC-09: Open-label first-line, single-arm phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer2026